Skip to main content
Premium Trial:

Request an Annual Quote

BD Posts 5 Percent Increase in Q3 Revenues

NEW YORK (GenomeWeb) – Becton Dickinson today reported a 5 percent jump in its third quarter revenues with growth across all three of its business segments.

The Franklin Lakes, NJ-based medical products, diagnostics, and research tools firm reported total revenues of $2.16 billion for the three months ended June 30, up from $2.05 billion for Q3 2013. It beat the average Wall Street estimate of $2.14 billion.

BD reported 5 percent sales growth for its BD Medical segment to $1.20 from $1.14 billion, while the BD Biosciences business reported 8 percent sales growth to $277 million for the quarter from $257 million in Q3 2013.

Its BD Diagnostics segment had nearly 4 percent revenue growth to $679 million from $655 million. Within that segment, its preanalytical systems sales climbed nearly 6 percent to $364 million from $345 million, and its diagnostic systems sales were up nearly 2 percent to $315 million from $310 million.

BD posted net income of $326 million, or $1.65 per share, compared to Q3 2013 net income of $302 million, or $1.52 per share. On an adjusted basis, its EPS was $1.68, beating analysts' consensus estimate of $1.67.

BD's R&D spending climbed 14 percent to $137 million from $121 million, while the firm cut its SG&A expenses around 1 percent to $528 million from $534 million.

The company reaffirmed its FY 2014 guidance of revenue growth between 4 percent and 4.5 percent, with EPS from continuing operations between $6.22 and $6.25.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.